Emtricitabine / tenofovir alafenamide Alternatives Compared
Emtricitabine / tenofovir alafenamide | Apretude (cabotegravir) | Truvada (emtricitabine / tenofovir disoproxil) |
|
---|
Emtricitabine / tenofovir alafenamide | Apretude (cabotegravir) | Truvada (emtricitabine / tenofovir disoproxil) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV, HIV Infection. Emtricitabine / tenofovir alafenamide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV. Apretude may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV, HIV Infection, Nonoccupational Exposure, Occupational Exposure. Truvada may also be used for purposes not listed in this medication guide. |
Related suggestions Pre-Exposure Prophylaxis of HIV
|
|||||||||||||||||||||||
More about Emtricitabine / tenofovir alafenamide | More about Apretude (cabotegravir) | More about Truvada (emtricitabine / tenofovir disoproxil) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Emtricitabine / tenofovir alafenamide has an average rating of 7.4 out of 10 from a total of 22 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 18% reported a negative effect. |
Apretude has an average rating of 9.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Truvada has an average rating of 6.2 out of 10 from a total of 40 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Apretude side effects |
View all Truvada side effects |
|||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
|
View all Apretude prices |
View all Truvada prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Descovy | Other cabotegravir brands include: Vocabria | Other emtricitabine / tenofovir disoproxil brands include: AccessPak for HIV PEP Basic | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
25.7 hours |
41 hours |
25.7 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 249 drugs are known to interact with Emtricitabine / tenofovir alafenamide:
|
A total of 66 drugs are known to interact with Apretude:
|
A total of 249 drugs are known to interact with Truvada:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
April 04, 2016 |
N/A |
August 02, 2004 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.